Combining ibrutinib with CAR-T cells: a promising therapeutic strategy in CLL

(1:29)

An Overview of a Study Combining Nivolumab With Ibrutinib in CLL and Richter Transformation

(1:18)

Saar Gill, MD: Combining CAR T-Cell Therapy With Ibrutinib in CLL Patients

(9:48)

Ibrutinib in combination with rituximab – the future of treating FL

(1:55)

Rationale for combining ibrutinib with tisa-cel in MCL

(1:13)

Ibrutinib and ublituximab – a promising combination regimen for treating CLL?

(5:35)

Sequencing and Combining Idelalisib and Ibrutinib

(1:40)

Rationale for Ibrutinib/CAR T-Cell Therapy Combination in CLL

(1:40)

Emerging ibrutinib-based combinations in CLL

(1:56)

Optimizing the combination of ibrutinib plus venetoclax in CLL

(2:46)

Ibrutinib resistance-mechanisms and options in CLL

(29:14)

Dr. Davids on the Combination of Ibrutinib and Obinutuzumab in CLL

(2:34)

PHOENIX: ibrutinib in combination with R-CHOP for DLBCL

(1:23)

Dr. Woyach on Using Ibrutinib in Combination Therapies

(1:53)

Selinexor for CLL - mechanism of action and combination with ibrutinib

(1:1econd)

CLL: Chemotherapy and Ibrutinib based regimens

(25:38)

Ibrutinib combined with TGR-1202 in CLL and mantle cell lymphoma (MCL): preliminary results

(1:11)

Results for the Combination of Nivolumab and Ibrutinib in Non-Hodgkin Lymphoma and CLL

(1:9)

Dr. Rogers on Benefits of Ibrutinib Combination in CLL

(1:17)

Ibrutinib combination therapy in CLL: overview of the data so far

(1:9)